- Sampaio-Dias, Ivo E.
- Maestro, Miguel
[Abstract] Melanostatin (MIF-1) is an endogenous positive allosteric modulator (PAM) of dopamine D2 receptors (D2R) with recognized therapeutic potential in central nervous system (CNS) disorders associated with dopaminergic dysfunction, particularly Parkinson’s disease. However, the therapeutic development of MIF-1 has been limited by poor pharmacokinetic properties. Building on previous studies of conformationally constrained MIF-1 analogs, the present work describes the design, synthesis, and comprehensive functional, toxicological, and permeability evaluation of new bridged derivatives incorporating the enantiopure scaffold (1R,3S,4S)-2-azanorbornane-3-carboxylic acid as a hybrid prolyl/pipecolyl surrogate. The target MIF-1 derivatives were synthesized through a concise and stereoselective route, and their absolute configuration was unequivocally established by X-ray crystallography. Pharmacological assays at human D2R identified four active derivatives (7b, 8d, 9c, and 9d) that potentiated dopamine responses by 5.3- to 6.6-fold at concentrations as low as 10 pM, consistent with PAM-like activity. Toxicological profiling in HepG2 (100 µM) and differentiated SH-SY5Y neuronal cells (up to 200 µM) confirmed that these compounds are well tolerated at supra-pharmacological concentrations, except for 9c. Additionally, these compounds exhibited reduced P-gp-mediated efflux and improved Caco-2 permeability compared to MIF-1. Overall, these findings identify 2-azanorbornane as a promising scaffold for the development of D2R PAM ligands with favorable pharmacokinetic and safety profiles., This work received financial support from PT national funds (FCT/MECI, Fundação para a Ciência e Tecnologia and Ministério da Educação, Ciência e Inovação) through project 2023.14440.PEX (DOI: 10.54499/2023.14440.PEX). FCT/MECI is also acknowledged for supporting project UID/50006/2025 - Laboratório Associado para a Química Verde - Tecnologias e Processos Limpos. I.E.S.-D. thanks FCT for funding through the Individual Call to Scientific Employment Stimulus with reference 2020.02311.CEECIND/CP1596/CT0004 (DOI: 10.54499/2020.02311.CEECIND/CP1596/CT0004). V.M.C. thanks the financial support and her grant funded by national funds from FCT, in the scope of the projects UIDP/04378/2020 (DOI: 10.54499/UIDP/04378/2020) and UIDB/04378/2020 (DOI: 10.54499/UIDB/04378/2020) of the Research Unit on Applied Molecular Biosciences (UCIBIO), and the project LA/P/0140/2020 (DOI: 10.54499/LA/P/0008/2020) of the Associate Laboratory Institute for Health and Bioeconomy – i4HB. H.F.C.-A., X.C.C., and B.L.P.-L. thank FCT for the Ph.D. grants UI/BD/154888/2023 (DOI:10.54499/UI/BD/154888/2023), 2024.02245.BD, and 2022.14060.BD (DOI: 10.54499/2022.14060.BD), respectively. X.G.-M. thanks Consellería de Cultura, Educación e Ordenación Universitaria of the Galician Government (grant: ED431B 2023/25) and Ministerio de Ciencia e Innovación – Agencia Estatal de Investigación (PID2021-124010OB-100) for the financial support, Portugal. Fundação para a Ciência e a Tecnologia; 2023.14440.PEX, Portugal. Fundação para a Ciência e a Tecnologia; UID/50006/2025, Portugal. Fundação para a Ciência e a Tecnologia; 2020.02311.CEECIND/CP1596/CT0004, Portugal. Fundação para a Ciência e a Tecnologia; UIDP/04378/2020, Portugal. Fundação para a Ciência e a Tecnologia; UIDB/04378/2020, Portugal. Fundação para a Ciência e a Tecnologia; LA/P/0140/2020, Portugal. Fundação para a Ciência e a Tecnologia; UI/BD/154888/2023, Portugal. Fundação para a Ciência e a Tecnologia; 2024.02245.BD, Portugal. Fundação para a Ciência e a Tecnologia; 2022.14060.BD, Xunta de Galicia; ED431B 2023/25